FDA inspection
Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc.: FDA inspection ending May 17, 2013
FDA inspection 833837 · Voluntary Action Indicated (VAI) · South San Francisco, CA
Key facts
| Inspection ID | 833837 |
|---|---|
| Firm | Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc. |
| FEI number | 3009255166 |
| Address | Onyx Pharmaceuticals, Inc., 249 E Grand Ave |
| City | South San Francisco |
| State | CA |
| ZIP | 94080 |
| Country | United States |
| Fiscal year | 2013 |
| Inspection end date | May 17, 2013 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Bioresearch Monitoring |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data